72.85
+5.12%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About KeyMed Biosciences
Its shares trade on HKEX under the ticker 2162.HK. It has been listed since 8 July 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥813.7m and a net loss of CN¥593.7m. At that date it held total assets of CN¥4.92bn and shareholders' equity of CN¥3.24bn.
Keymed Biosciences, Inc. is an investment holding company, which engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2021-07-08. The firm focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The firm has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The firm has also established a fully integrated platform covering the key functions of biopharmaceutical development. The firm's main products include CM310, CM326 and CMG901.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Jul 2021
- Employees
- 750
- Website
- keymedbio.com ↗
Leadership
Pay as last reported
- Dr. Bo ChenExecutive Chairman of the Board, Chief Executive Officer, since 2018CN¥231,000
- Mr. Yanrong ZhangChief Financial Officer, Company Secretary
- Dr. Changyu WangSenior Vice President, Executive Director, since 2021
- Dr. Qian JiaVice President
- Dr. Gang XuExecutive Director, since 2018CN¥940,000
- Dr. Jinchun YanChief Medical Officer
- Ms. Vivien Pak Yu TamCompany Secretary
- Mr. Qi ChenNon-Executive Director
- Mr. Yilun LiuNon-Executive Director
- Dr. Min Chuan WangNon-Executive Director
- Prof. Yang KeNon-Executive Independent DirectorCN¥309,000
- Mr. Cheuk Kin LawNon-Executive Independent DirectorCN¥371,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company focuses on autoimmune and oncology therapeutic areas with innovative biological therapies.
- Has mastered in-house drug discovery and development technologies including antibody platforms.
- Employs 750 full-time employees with a fully integrated biopharmaceutical development platform.
Weaknesses
- Company is an investment holding company with no specific product sales mentioned.
- No information provided on revenue or financial performance metrics.
- IPO occurred in 2021, suggesting limited market history and potential early-stage risks.
Opportunities
- Potential for growth in autoimmune and oncology therapeutic areas with underserved medical needs.
- Innovative platforms could lead to new product development and market expansion.
- Established fully integrated platform may facilitate faster development cycles and cost efficiencies.
Threats
- No information on competitors or market saturation in autoimmune and oncology sectors.
- Investment holding company structure may face regulatory or market challenges.
- Limited market history since IPO in 2021 could impact investor confidence.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.